annual Report 2009 - STRATEC Biomedical AG

Overall, the development in intangible assets added due to company acquisitions was as follows:
in v thousand 2009 2008
01.01. 2,191 3,746
Additions due to company acquisitions 2,373 0
Scheduled amortization -824 -836
Currency translation 159 -719
12.31. 3,897 2,191
No further development expenses were capitalized in the year under report.
The expenses for research and project supervision, as well as development expenses not meeting the criteria for capitalization
set out in IAS 38, amounted to u 4,469 thousand (previous year: u 5,397 thousand) and have been recognized,
mostly under “Personnel expenses”, in the statement of comprehensive income. Moreover, expenses of u 932 thousand
were incurred in the period under report for the procurement of materials for use in research and development (previous
year: u 671 thousand). These expenses are included in cost of materials.
The development in intangible assets from January 1 to December 31, 2009 has been presented in the annex to the notes
to the consolidated financial statements.
(2) Property, plant and equipment
In the interests of simplification, assets with costs of acquisition of u 150.00 to u 1,000.00 are subject to straightline
depreciation over five years irrespective of their individual useful lives. Depreciation amounted to u 52 thousand
(previous year: u 21 thousand). Moreover, in accordance with foreign tax simplification procedures, immediate tax
write-downs of u 39 thousand (previous year: u 10 thousand) were included without amendment in the consolidated
financial statements.
Investments in property, plant and equipment were structured as follows:
in v thousand 2009 2008
Land 657 0
Cars 221 87
Internally produced test analyzer systems and inspection materials 625 456
Tools 679 603
IT components 75 29
Plant and office equipment 366 147
Prepayments made for company buildings 805 0
Prepayments made for tools 317 109
“Test analyzer systems and inspection materials” mainly involve testing systems and prototypes developed internally by
the company. The respective own work capitalized of u 625 thousand for the year under report (previous year: u 456 thousand)
is subject to scheduled straight-line depreciation in line with the actual decline in use over an expected useful life
of three years.
70 stratec Annual Report 2009